Tesla's problems, Eli Lilly's weight loss pill, and egg prices surge: Business news roundup
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
STAT3d
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
How Much Should Weight Loss Drugs Cost?
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.